TORONTO--Cobequid Life Sciences here and the Netherlands-based Qiagen announced an agreement to exploit the potential of DNA vaccines in aquaculture. Cobequid will gain nonexclusive access, limited to use for its aquaculture products, to specific components of Qiagen's proprietary DNA manufacturing technology targeted to gene therapy and genetic vaccination applications.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.